{"id":"long-acting-somatostatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia / glucose intolerance"},{"rate":null,"effect":"Gallstone formation (cholelithiasis)"},{"rate":null,"effect":"Abdominal pain / gastrointestinal disturbance"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Somatostatin is a naturally occurring inhibitory peptide hormone that suppresses the release of growth hormone, insulin, glucagon, and other hormones. Long-acting formulations extend the duration of action, allowing for less frequent dosing. These analogs bind to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells and tumor cells, providing sustained inhibition of hormone secretion and potential anti-proliferative effects.","oneSentence":"Long-acting somatostatin is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:21.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acromegaly"},{"name":"Neuroendocrine tumors"},{"name":"Carcinoid syndrome"}]},"trialDetails":[{"nctId":"NCT06991738","phase":"PHASE1, PHASE2","title":"177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2026-04-01","conditions":"Thyroid Cancer","enrollment":18},{"nctId":"NCT04837040","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly","status":"ACTIVE_NOT_RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2021-05-12","conditions":"Acromegaly","enrollment":58},{"nctId":"NCT02713776","phase":"PHASE2","title":"Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-12-13","conditions":"Enterostomy","enrollment":57},{"nctId":"NCT06878664","phase":"PHASE3","title":"Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-06-12","conditions":"Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)","enrollment":166},{"nctId":"NCT06345079","phase":"PHASE2","title":"Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours","status":"RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2024-10-14","conditions":"Neuroendocrine Tumors","enrollment":78},{"nctId":"NCT06372652","phase":"PHASE1","title":"A Phase 1 Study of TE-8214 Solution in Healthy Volunteers","status":"COMPLETED","sponsor":"Immunwork, Inc.","startDate":"2024-06-18","conditions":"Acromegaly","enrollment":32},{"nctId":"NCT03289741","phase":"PHASE4","title":"A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-19","conditions":"Neuroendocrine Tumors","enrollment":51},{"nctId":"NCT06855095","phase":"PHASE2, PHASE3","title":"Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-06-25","conditions":"Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2","enrollment":39},{"nctId":"NCT01371045","phase":"","title":"Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2011-06","conditions":"Acromegaly","enrollment":""},{"nctId":"NCT05701241","phase":"PHASE4","title":"Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2023-06-28","conditions":"Gastroenteropancreatic Neuroendocrine Tumor","enrollment":270},{"nctId":"NCT03377660","phase":"","title":"Resection of the Esophagus and Subsequent Weight Loss","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2018-01-01","conditions":"Esophageal Cancer, Weight Gain, Eating Behavior","enrollment":30},{"nctId":"NCT05884255","phase":"PHASE3","title":"An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-07-06","conditions":"Advanced Gastroenteropancreatic Neuroendocrine Tumor","enrollment":220},{"nctId":"NCT03967249","phase":"PHASE2","title":"Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2019-07-25","conditions":"Acromegaly","enrollment":39},{"nctId":"NCT02152124","phase":"","title":"Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2014-06-01","conditions":"Acromegaly","enrollment":21},{"nctId":"NCT03548415","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2018-09-13","conditions":"Acromegaly","enrollment":43},{"nctId":"NCT02749227","phase":"PHASE2","title":"Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors","status":"TERMINATED","sponsor":"Columbia University","startDate":"2017-07-10","conditions":"Pituitary Tumor, ACTH-producing Pituitary Tumour","enrollment":4},{"nctId":"NCT00446082","phase":"PHASE1","title":"Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-06","conditions":"Carcinoid Tumor, Acromegaly","enrollment":85},{"nctId":"NCT03613623","phase":"","title":"Acromegaly: Patient And Physician Perspectives","status":"COMPLETED","sponsor":"Tulane University","startDate":"2018-07-02","conditions":"Acromegaly","enrollment":152},{"nctId":"NCT04129255","phase":"PHASE2","title":"Octreotide LAR in the Induction of Immunologic Response in NENs Patients","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2017-06-28","conditions":"Neuroendocrine Tumors","enrollment":34},{"nctId":"NCT00092287","phase":"PHASE3","title":"Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome","status":"TERMINATED","sponsor":"Ipsen","startDate":"2004-07","conditions":"Malignant Carcinoid Syndrome","enrollment":4},{"nctId":"NCT04138342","phase":"PHASE1","title":"Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer","status":"UNKNOWN","sponsor":"Al-Azhar University","startDate":"2019-09-15","conditions":"Breast Cancer, Skin Cancer, Skin Diseases","enrollment":30},{"nctId":"NCT02705651","phase":"PHASE3","title":"Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2019-12","conditions":"Pancreatic Neuroendocrine Tumors in MEN1","enrollment":180},{"nctId":"NCT03812939","phase":"","title":"Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-01-01","conditions":"Gastric NET","enrollment":30},{"nctId":"NCT02874326","phase":"PHASE2","title":"Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2016-10","conditions":"Hereditary Hemorrhagic Telangiectasia, Gastrointestinal Hemorrhage, Anemia","enrollment":15},{"nctId":"NCT01377246","phase":"PHASE3","title":"Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2011-05","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":100},{"nctId":"NCT00600886","phase":"PHASE3","title":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-02-11","conditions":"Acromegaly","enrollment":358},{"nctId":"NCT02668172","phase":"PHASE4","title":"Pasireotide LAR and Pegvisomant Study in Acromegaly","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2015-08","conditions":"Acromegaly","enrollment":60},{"nctId":"NCT02427295","phase":"PHASE4","title":"Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2014-03","conditions":"Acromegaly","enrollment":1},{"nctId":"NCT02119052","phase":"PHASE2, PHASE3","title":"Effects of Somatostatin on Liver in ADPKD","status":"COMPLETED","sponsor":"Federico II University","startDate":"2009-01","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":35},{"nctId":"NCT00690430","phase":"PHASE3","title":"Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04","conditions":"Symptomatic Refractory Resistant Carcinoid Disease","enrollment":186},{"nctId":"NCT00309283","phase":"PHASE3","title":"Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2006-04","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":78},{"nctId":"NCT01203306","phase":"PHASE2","title":"Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2006-01","conditions":"Neuroendocrine Carcinomas","enrollment":42},{"nctId":"NCT01188733","phase":"PHASE1, PHASE2","title":"Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"1998-06","conditions":"Cirrhosis, Portal Hypertension, Esophageal Varices","enrollment":39},{"nctId":"NCT00642720","phase":"PHASE4","title":"Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2006-10","conditions":"Quality of Life, Acromegaly","enrollment":20},{"nctId":"NCT00121914","phase":"PHASE3","title":"Treatment of Hepatocellular Carcinoma: Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2000-10","conditions":"Carcinoma, Hepatocellular","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Long-acting somatostatin","genericName":"Long-acting somatostatin","companyName":"Mario Negri Institute for Pharmacological Research","companyId":"mario-negri-institute-for-pharmacological-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Long-acting somatostatin is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors. Used for Acromegaly, Neuroendocrine tumors, Carcinoid syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}